http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108144061-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3515 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-141 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 |
| filingDate | 2018-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108144061-B |
| titleOfInvention | Application of microRNA-210 inhibitors in the preparation of drugs for the treatment of inflammatory skin diseases |
| abstract | The invention discloses the application of a microRNA-210 inhibitor in preparing a medicine for treating inflammatory skin diseases. The inventors have proved through a large number of experiments that inhibiting the expression of microRNA-210 in vitro can significantly enhance the expression of its target gene STAT6, thereby inhibiting the proliferation of keratinocytes and the secretion of the chemokine CCL20, and further inhibiting the proliferation of its chemotactic T cells to the skin lesions. At the same time, it can also inhibit the differentiation of TH1 and TH17 . Knockout of microRNA-210 and intralesional injection of microRNA-210 inhibitor (cholesterol-modified antagomiR-210) to specifically inhibit the expression of microRNA-210 can significantly inhibit skin inflammation in mice and improve T cell immune imbalance. The present invention provides a new pathophysiological mechanism for inflammatory skin diseases, and provides a new strategy for preparing medicines for treating inflammatory skin diseases. |
| priorityDate | 2018-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 50.